Gisela Schwab, MD
The FDA has granted a priority review to a supplemental new drug application (sNDA) for cabozantinib (Cabometyx) for previously untreated patients with advanced renal cell carcinoma (RCC), according to Exelixis, the developer of the multikinase inhibitor.
Cabozantinib is approved by the FDA as a treatment for patients with advanced RCC who have received prior antiangiogenic therapy.
Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591-597. doi:10.1200/JCO.2016.70.7398.
... to read the full story